Skip to main content
Premium Trial:

Request an Annual Quote

CeMines Establishes New Division for Genomics-Related Products and Services

NEW YORK, Aug. 4 (GenomeWeb News) -- Biotech company CeMines, of Evergreen, Colo., said last week that it has created a biosystems division that will focus on offering genomics-related research tools and services to the research and drug discovery market.


"We have the existing infrastructure necessary to enable CeMines to immediately accelerate the growth of sales from our existing product line of research tools, including antibodies, cDNA, and mRNA, and at the same time commence with our market introduction of a new family of products targeted at establishing CeMines as a premier brand in drug discovery and other markets," Roger Attick, president and CEO of CeMines said in an official statement.


Founded in 2000, the company has primarily uses gene regulation technology to help develop diagnostics and therapeutics for cancer. In June, the company expanded its diagnostics and therapeutics division and moved it to a new facility in La Jolla, Calif.


CeMines is attempting to commercialize its patent-pending Molecular FingerPrinting technology to aid in developing early-stage diagnostics and targeted therapeutics, the company said.